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A 53 year-old nonsmoking Chinese man
with a long-standing diagnosis of asthma
presented with a 1-week history of worsening
shortness of breath, productive cough, and
pleuritic chest pain. Chest X ray confirmed
right-middle lobe consolidation suggestive of
pneumonia. His symptoms resolved with a
5-day course of antibiotics, but a follow-up
chest X ray demonstrated worsening of the
consolidation. Bronchoscopy revealed a right
middle-lobe tumor, and the biopsy was posi-
tive for small-cell lung carcinoma. 
The patient was born in Hong Kong and
immigrated to Canada around 1990 at
40 years of age. According to his medical his-
tory, at 6 years of age he was diagnosed with
asthma, which was treated with Chinese tradi-
tional medicine (CTM) pills known to con-
tain arsenic until he was 16 years of age, when
he was diagnosed with Bowen’s disease. In
1993, a skin biopsy of a lesion on his right
elbow was positive for squamous cell carci-
noma in situ. He had never smoked cigarettes,
and he drank alcohol only once a month. He
had no other known exposures to arsenic
through drinking water, diet, or occupation. 
When seen by the medical oncologist, he
complained of a cough that produced clear
sputum and dull pain over the right costal
margin, but he denied constitutional symp-
toms. A physical exam revealed an afebrile
Asian male with no palpable lymphade-
nopathy. Chest examination was consistent
with right middle lobe consolidation. The
liver edge was palpable 3 cm below the costal
margin but was neither nodular nor tender.
Multiple 3–8 cm scaly, purple-brown, well-
demarcated tear-drop–shaped patches were
distributed over the skin of his trunk and
extremities; these patches were consistent with
his history of Bowen’s disease. His neurologic
examination was normal. 
Computed tomography of the patient’s
chest and abdomen confirmed a right hilar
mass completely obstructing the right mid-
dle-lobe bronchus with distal pneumonitis
and large mediastinal nodes. Multiple hypo-
dense liver lesions suggestive of metastatic dis-
ease were also found. 
A diagnosis of extensive stage small-cell
lung cancer was made. The patient entered a
phase III clinical trial comparing cisplatin and
etoposide to cisplatin and irinotecan and was
randomized to the latter arm. Because more
than 35 years had passed since the cessation
of his known arsenic exposure, direct testing
to confirm a diagnosis of arsenic exposure
would probably have served little purpose.
He achieved a complete remission but died
of complications of progressive disease
10 months later.
Discussion
Arsenic, a naturally occurring metal, is best
known as a poison and can generate both acute
and chronic toxicity. Exposure can occur
through air, water, soil, and food. Less well
known is that arsenic has been used medici-
nally to treat a variety of illnesses since the
times of Hippocrates and Galen. In the 18th
and 19th centuries, Fowler’s solution (contain-
ing 1% arsenic trioxide) was prescribed to treat
asthma, psoriasis, syphilis, and chronic myel-
ogenous leukemia (Waxman and Anderson
2001). Although the association of inorganic
arsenic intake and malignancy was ﬁrst docu-
mented in 1887 (Hutchison 1887), Fowler’s
solution continued to be popularized as a
health tonic and was listed in the British
Pharmaceutical and Therapeutic Products hand-
book as recently as 1958 (Ratnaike 2003). 
With the advent of other pharmaceuticals
and the discovery of the complications of
chronic arsenic exposure, therapeutic arsenic
use has declined. By the mid-1990s, the only
indication for arsenic was in the treatment of
trypanosomiasis (Waxman and Anderson
2001). However, intravenous arsenic trioxide
has recently been shown to induce remission
in patients with acute promyelocytic
leukemia (Soignet et al. 1998), prompting a
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Chronic arsenic toxicity occurs primarily through inadvertent ingestion of contaminated water
and food or occupational exposure, but it can also occur through medicinal ingestion. This case
features a 53-year-old lifetime nonsmoker with chronic asthma treated for 10 years in childhood
with Chinese traditional medicine containing arsenic. The patient was diagnosed with Bowen’s
disease and developed extensive-stage small-cell carcinoma of the lung 10 years and 47 years,
respectively, after the onset of arsenic exposure. Although it has a long history as a medicinal
agent, arsenic is a carcinogen associated with many malignancies including those of skin and lung.
It is more commonly associated with non–small-cell lung cancer, but the temporal association
with Bowen’s disease in the absence of other chemical or occupational exposure strongly points to
a causal role for arsenic in this case of small-cell lung cancer. Individuals with documented arsenic-
induced Bowen’s disease should be considered for more aggressive screening for long-term compli-
cations, especially the development of subsequent malignancies. Key words: arsenic, Bowen’s
disease, case report, Chinese traditional medicine, chronic toxicity, small-cell lung carcinoma.
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Environmental Medicine Grand Rounds resurgence in its therapeutic use. In 2000, the
U.S. Food and Drug Administration (FDA)
approved the drug Trisenox (arsenic tri-
oxide; Cell Therapeutics, Inc., Seattle, WA,
USA) only 3 years after studies were initiated
(FDA 2001).
In our patient, chronic arsenic exposure
occurred by consuming Chinese herbal anti-
asthmatic preparations in Hong Kong, most
likely between 1956 and 1966. Although these
medicines were widely available throughout
Asia, their use was ﬁrst described in Singapore
by Tay and Seah (1975). They identified
preparations containing high concentrations
of inorganic arsenic ranging from 25 to
107,000 mg/L, with six of these preparations
having been imported from Hong Kong.
Arsenic continues to be either a main con-
stituent or a contaminant in many traditional
and herbal medicines. An analysis of Asian
traditional medicines by Garvey et al. (2001)
revealed that 4 of the 54 (7.4%) sampled pills
would result in a daily arsenic dosage of
> 0.1 mg/day, whereas other pills contained
significant quantities of mercury or lead.
Containing daily dosages of arsenic that
ranged from 0.140 to 16.1 mg, these pills
were indicated for the treatment of asthma,
headache, fever, and children’s ailments and
to clear the kidneys and lungs (Garvey et al.
2001). Although manufactured in Southeast
Asia, two of the pills were purchased in the
United States (Garvey et al. 2001). In recent
decades, there has been growing interest and
availability of traditional Asian medicines.
Currently, the FDA has not imposed any
standard limits for arsenic in food or medi-
cine except in animals treated with veterinary
drugs [Agency for Toxic Substances and
Disease Registry (ATSDR) 2004]. 
The toxicity of arsenic depends on its
chemical state. Inorganic arsenic in its tri-
valent form is more toxic than pentavalent
arsenic (Hughes 2002). By binding to thiol or
sulfhydryl groups on proteins, As(III) can
inactivate over 200 enzymes (Abernathy et al.
1999; Hughes 2002). This is the likely
mechanism responsible for arsenic’s wide-
spread effects on the liver, lungs, kidneys,
spleen, gastrointestinal tract, and keratin-rich
tissues. As(V) can replace phosphate, which is
involved in many biochemical pathways
resulting in the depletion of compounds such
as adenosine-5´-triphosphate (ATP) (Hughes
2002). Increased levels of reactive oxidants in
plasma (Wu et al. 2001) and markers of
oxidative damage in arsenic-related skin con-
ditions (Matsui et al. 1999) suggest that long-
term damage from chronic arsenic exposure is
mediated through the generation of reactive
oxygen species.
Investigations of the effects of arsenic in
animals have been problematic (Wang JP et al.
2002), and it is uncertain whether inorganic
arsenic itself or resultant methylated metabo-
lites that form in vivo are responsible for the
carcinogenic effect. The few studies that have
been successful, however, confirm arsenic’s
carcinogenicity. Arsenic is likely a cocarcino-
gen that inhibits DNA repair and enhances
the activity of other directly genotoxic agents
(Andrew et al 2003; Beyermann 2002;
Rossman et al. 2002). The cellular response to
arsenic exposure seems to be concentration
dependent. At high concentrations (> 50 µM),
arsenic is able to induce an apoptotic response
in vitro, a phenomenon probably exploited in
its use to treat leukemia (Jimi et al 2004;
Lunghi et al 2004). At lower concentrations
(< 25 µM), evidence of genomic stress can be
observed in the form of nuclear accumulation
of p53, but apoptosis is not generally seen
(Dong 2002). Environmental exposure to
arsenic in a chronic low-dose manner likely
leads to the gradual accumulation of genomic
damage without apoptosis. Other observations
suggest that the role of arsenic as a cocarcino-
gen may be mediated by inhibition of DNA
repair and increased expression of cyclin D1
(Vogt and Rossman 2001). Differences in the
expression pattern of p53 have also been
attributed to the down-regulation of gene
expression by alteration of promoter methyla-
tion status (Mass and Wang 1997). Arsenic
has been shown to modulate cell signaling by
inducing mitogen-activated protein kinases to
change gene expression (Beyersmann 2002;
Yang and Frenkel 2002). 
Diagnosis of arsenic intoxication is often
difficult because clinical presentation varies
depending on route of exposure, chemical
form, dose, and time elapsed since exposure.
Furthermore, because arsenic affects multiple
systems, poisoning can present with a wide
variety of signs and symptoms. In acute
arsenic poisoning, initial symptoms are
gastrointestinal in nature due to the direct
toxic effect of arsenic on intestinal epithelial
cells. Clinical features include colicky
abdominal pain, nausea, vomiting, bloody or
rice-water diarrhea, and excessive salivation.
Other manifestations include acute psychosis,
cardiomyopathy, pulmonary edema, renal
failure, skin rash, anemia, and encephalo-
pathy (Ratnaike 2003). Quantitative studies
can be performed on blood and urine in acute
arsenic poisoning to conﬁrm a suspected diag-
nosis. Because arsenic is cleared from blood
within 10 hr (Hindmarch 2002), a urine
arsenic level is usually more useful in cases of
recent ingestion within 1–3 days (Buchet
et al. 1981). Residual traces of arsenic in hair
and nail samples may confirm arsenic expo-
sure but can be subject to external contami-
nation and cannot reliably date time of
exposure (Hindmarch 2002). Presence of ane-
mia, leukopenia, thrombocytopenia, or
eosinophilia on complete blood count,
basophilic stippling on the peripheral smear,
or elevated liver transaminases is consistent
with arsenic exposure but is not speciﬁc. 
Like acute arsenic poisoning, the clinical
features of chronic arsenic exposure are multi-
systemic. Symptoms include malaise, weak-
ness, decreased appetite, weight loss, and a
sensory peripheral neuropathy that progresses
to glove and stocking anesthesia (Ratnaike
2003). However, the hallmark of long-term
arsenic exposure involves cutaneous changes
such as hyperkeratosis, hyperpigmentation,
Mee’s lines on nails, and malignant skin
changes including Bowen’s disease, squamous-
call carcinoma, and basal-cell carcinoma
(Centano et al. 2002; Wong SS 1998).
Although cutaneous changes develop slowly
over time (up to 3–7 years for pigmentation
changes and keratoses and up to 40 years for
skin cancer), they may occur after lower doses
than those causing neuropathy or anemia
(ATSDR 2004). Studies on populations with
chronic exposure to arsenic through drinking
water show an association with increased
cardiovascular disease (Tseng et al. 2003;
Wang CH et al. 2002), peripheral vascular dis-
ease (Wang CH et al. 2002; Wang et al. 2003;
Yu et al. 2002), cerebrovascular disease (Wang
CH et al. 2002), respiratory disease (Milton
and Rahman 2002), and diabetes (Wang et al.
2003). The most serious long-term conse-
quence of arsenic exposure is increased risk for
malignancy. Arsenic is now a recognized car-
cinogen associated with increased incidence of
skin, lung, liver, bladder, and kidney malig-
nancies (Chen et al. 1992). 
A positive dose–response relationship
between arsenic exposure and its chronic health
effects has been observed. In a large population
study in West Bengal, the prevalence of both
skin lesions and hyperpigmention increased
with the concentration of arsenic in drinking
water (Mazumder et al. 1998). For levels of
arsenic > 0.80 mg/L, the prevalence of skin
lesions and hyperpigmentation in males was
10.7 and 22.7 per 100, respectively (Mazumder
et al. 1998). A similar trend was noted in a
Taiwanese study; for arsenic levels > 0.60 mg/L,
the prevalence of skin cancer by 60 years of age
was 92.0 in 1,000 (Tseng et al. 1968). In a
recent review of the dose–response relationship
between arsenic consumption through drinking
water and its adverse health effects, Yoshida
et al. (2004) noted that skin lesions are the
most sensitive feature and often the earliest
nonmalignant effect of arsenic exposure.
Although a dose–response relationship between
arsenic and certain malignancies including lung
cancer was ﬁrst identiﬁed in 1989 on the basis
of a maximum 22-year latency period (Wu
et al. 1989), more recent data have quantiﬁed
that only arsenic exposure levels > 0.64 mg/L
are associated with a signiﬁcant increase in lung
cancer mortality (Guo 2004). 
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results in prolonged toxic exposure at doses
higher than those present in contaminated
water (Garvey et al. 2001; Tay and Seah
1975). Because both types of exposure involve
trivalent arsenic and occur through the same
mechanism of oral consumption followed by
gastrointestinal absorption, it is possible that
epidemiologic data from studies of drinking-
water exposure may be applied to medicinal
arsenic exposure. In 1998, case reports of three
patients with chronic arsenic poisoning from
CTMs in Singapore document that all three
had cutaneous changes including basal-cell
carcinoma and squamous-cell carcinoma, one
had lung cancer, and one had liver cancer
(Wong ST et al. 1998). 
Another case review of 17 patients from
Singapore selected for arsenic-induced cuta-
neous changes found that 15 were exposed
through CTMs (Wong SS et al. 1998). All the
patients had Bowen’s disease that developed
after a long average latency period of 39 years.
Since 1995, CTMs containing > 5 mg/L inor-
ganic arsenic have been banned in Singapore
(Wong SS et al. 1998). 
Skin lesions generally precede the onset of
internal malignancies. In a study of patients
who took Fowler’s solution (containing 1%
arsenic trioxide) during 1945–1969, approxi-
mately 50% had arsenic-related skin changes
(Cuziek et al. 1982). A follow-up report
10 years later demonstrated excess bladder
cancer mortality in the subgroup of patients
with skin changes (Cuziek et al. 1992). In a
study in Japan, Miki et al. (1982) reported
that of 31 patients with Bowen’s disease and
increased arsenic levels through drinking
water, 10 had invasive skin cancers and 10 had
internal malignancies, including 7 patients
with pulmonary cancers. The authors hypoth-
esized a timeline in which exposure to arsenic
was followed by Bowen’s disease within
10 years, invasive skin cancers after 20 years,
and pulmonary cancers after 30 years. Given
the long period for the development of
arsenic-induced malignancy, it may be too
early to see cases arising from areas currently
affected by contaminated drinking water such
as West Bengal, Bangladesh, and China. In
our patient, exposure likely started at approxi-
mately 6 of age, with his Bowen’s disease and
pulmonary cancer diagnosed 10 and 47 years
later, respectively. 
Multiple studies have demonstrated that
arsenic exposure is a documented risk factor
for the development of lung carcinoma. This
was best shown in a study in Nakajo, Japan
(Nakadaira et al. 2002), in which some resi-
dents were exposed to well water with inor-
ganic arsenic levels as high as 400 mg/L
during 1954–1959. Of 454 inhabitants who
underwent medical examinations in 1959,
93 (20.5%) were diagnosed as having chronic
arsenic poisoning on the basis of physical signs
including cutaneous changes. Twenty-nine
years after the exposure was terminated,
exposed male patients demonstrated an excess
mortality rate from lung cancer: the ratio of
observed deaths to expected deaths from lung
cancer was 7.0:0.64. Although arsenic expo-
sure is more commonly associated with
non–small-cell lung cancer, small-cell carci-
noma incidence was also increased when com-
pared with control groups, thereby supporting
a causal relationship between arsenic and
small-cell lung cancer. However, smoking was
a confounding factor that was not addressed in
the study design. 
Bowen’s disease (squamous-cell carcinoma
in situ), which can arise as a consequence of
both arsenic and exposure to ultraviolet (UV)
radation, seems a natural platform from which
to study carcinogenic changes. A large popula-
tion-based Danish cohort study confirmed
that patients with Bowen’s disease have an
excess risk of nonmelanomatous skin cancer
and found a 2-fold increase in the risk of lung
cancer in male patients with Bowen’s disease
on sun-protected areas (Jaeger et al. 1999).
The different mutagenic mechanisms associ-
ated with arsenic compared with those of
other genotoxic agents have been reﬂected in
mutational spectra of specific genes. Subtle
differences have been noted in the mutation
spectrum of UV-induced Bowen’s disease, in
which point mutations are common, in con-
trast to arsenic-induced skin lesion, for which
few p53 mutations were observed (Castren
et al. 1998; Hsieh et al. 1994). Whether such
observations can be translated from cutaneous
lesions to bronchial neoplasms is unclear, but
it seems likely that a different mutational spec-
trum may be seen in arsenic-induced versus
smoking-induced small-cell lung cancers. 
Small-cell lung cancer is an aggressive
tumor that metastasizes early. Patients often
present with extensive disease, which has a
poor prognosis. It is extremely rare in young
nonsmokers, so such a diagnosis should pro-
voke a search for other risk factors. In the pre-
sent case, the only risk factor was a remote
10-year history of arsenic ingestion through
CTMs. Physical examination revealed the pres-
ence of cutaneous lesions that had been previ-
ously biopsied to show the presence of Bowen’s
disease. Although peripheral neuropathy was
absent, we felt that his cutaneous and lung
neoplasms served to indirectly conﬁrm his his-
tory of remote chronic arsenic exposure.
Conclusion
Chronic arsenic toxicity is a clinical diagnosis.
It can be difficult to elicit a clear history of
exposure either to contaminated food or well
water, or through occupational exposure.
However, it is a diagnosis that should be con-
sidered if there is a clear history of traditional
or herbal medication use, particularly for the
treatment of asthma, psoriasis, or syphilis.
Moreover, chronic arsenic toxicity should be
suspected in anyone presenting with cuta-
neous changes such as hyperkeratosis, hyper-
pigmentation, Mee’s lines on nails, or
malignant skin changes such as Bowen’s dis-
ease with or without concomitant peripheral
neuropathy.
Arsenic is a recognized etiologic factor in
Bowen’s disease and a known risk factor for
lung cancer. In our patient, it is likely that
each condition developed independently fol-
lowing arsenic exposure, with skin pathology
preceding lung cancer. Although a unifying
pathophysiologic mechanism remains to be
elucidated, patients with a history of arsenic
exposure or ingestion of antiasthmatic CTMs
require additional vigilance for signs of skin
changes that may herald other malignancies.
As chronic arsenic exposure through contami-
nated drinking water continues in many areas
of the world, a large population may be at risk
for latent malignancy, particularly if skin
changes have already been noted. Because the
role of chemopreventative approaches in these
patients remains to be proven, such individu-
als should be considered candidates for
chemoprevention trials. 
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